Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKoçak, Abdullah Osman
dc.contributor.authorDogruyol, Sinem
dc.contributor.authorAkbaş, Ilker
dc.contributor.authorMenekse, Tugba Sanalp
dc.contributor.authorGür, Sultan Tuna Akgöl
dc.contributor.authorKoçak, Meryem Betos
dc.contributor.authorÇakır, Zeynep
dc.contributor.authorOrun, Serhat
dc.date.accessioned2022-05-11T14:37:02Z
dc.date.available2022-05-11T14:37:02Z
dc.date.issued2020
dc.identifier.issn0735-6757
dc.identifier.issn1532-8171
dc.identifier.urihttps://doi.org/10.1016/j.ajem.2020.05.104
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8537
dc.description.abstractBackground: This study aimed to compare the analgesic efficacy of topical capsaicin and topical piroxicam in acute musculoskeletal injuries. Methods: This is a prospective, randomized, controlled, double-blinded study. The data for the 67 patients in the piroxicam group and the 69 in the capsaicin group were examined. The initial visual analog scale (VAS) scores were compared with the 60th and 120th minute as well as the 24th and 72nd hour values. Differences between the VAS scores, clinical effectiveness of the treatment and side effects were evaluated. Results: In the capsaicin group, the mean difference in the delta VAS scores was significantly higher at each measurement time. The mean of the percentage of reduction in the VAS scores of the topical capsaicin group was significantly higher than that in the topical piroxicam group. The highest difference in terms of both outcomes was determined at the 72nd hour VAS change. Mean differences were 1.53 (95% CI: 0.85-2.221) and 19.7 (95% CI: 12.4-27.2) respectively (p < 0.001). In the capsaicin group, the clinical effect of the treatment was found significantly higher (p < 0.01). The difference between the clinical effectiveness of the groups regarding the treatment outcomes was also statistically significant (p < 0.001). There was no significant difference between the patient groups regarding the presence of side effects. Conclusion: Topical capsaicin can be used as an alternative to topical piroxicam initially and at follow-up in patients presenting to the emergency department with acute pain as there were no observable differences in side-effects between the two groups. (c) 2020 Elsevier Inc. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherW B Saunders Co-Elsevier Incen_US
dc.identifier.doi10.1016/j.ajem.2020.05.104
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGelen_US
dc.subjectPlaceboen_US
dc.subjectNeuropathyen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectPatchen_US
dc.titleComparison of topical capsaicin and topical piroxicam in the treatment of acute trauma-induced pain: A randomized double-blind trialen_US
dc.typearticleen_US
dc.relation.ispartofAmerican Journal of Emergency Medicineen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Acil Tıp Ana Bilim Dalıen_US
dc.authorid0000-0002-6949-7233
dc.authorid0000-0003-3348-8375
dc.authorid0000-0001-5879-7858
dc.identifier.volume38en_US
dc.identifier.issue9en_US
dc.identifier.startpage1767en_US
dc.identifier.endpage1771en_US
dc.institutionauthorOrun, Serhat
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid56712496500
dc.authorscopusid57195677350
dc.authorscopusid56712815300
dc.authorscopusid57218292761
dc.authorscopusid55673370200
dc.authorscopusid57212381695
dc.authorscopusid56536983100
dc.authorwosidKocak, Abdullah Osman/AAO-7235-2021
dc.authorwosidDogruyol, Sinem/ABC-3555-2021
dc.authorwosidOrun, Serhat/AAB-2040-2020
dc.authorwosidÇekmen, Bora/ABE-2326-2020
dc.identifier.wosWOS:000580647500012en_US
dc.identifier.scopus2-s2.0-85088654212en_US
dc.identifier.pmid32739846en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster